https://www.andorrahealthwatch.com/article/904355152-gelatin-trick-recipe-under-investigation-the-viral-doctor-approved-jello-weight-loss-hack-claims-evaluated-for-gelatide-drops Andorra Health Watch en PressRelease 2026-04-07T19:14:40+00:00 Gelatin Trick Recipe Under Investigation: The Viral Doctor-Approved Jello Weight Loss Hack Claims Evaluated for Gelatide Drops https://zingfast.com/wp-content/uploads/2026/04/Gelatin-Trick-Recipe.jpg https://www.andorrahealthwatch.com/article/904354949-lemaitre-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-07T18:39:10+00:00 LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/8b8755b7-6f04-4650-9c94-0a2d0654fd49/small/lemaitre-2color-rgb-jpg.jpg https://www.andorrahealthwatch.com/article/899803312-doctor-i-lanza-la-primera-ia-que-recomienda-seguros-de-salud-con-precios-reales Andorra Health Watch en PressRelease 2026-04-07T06:15:00+00:00 Doctor i lanza la primera IA que recomienda seguros de salud con precios reales https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24803456-doctor-i-ia-1322x988.png https://www.andorrahealthwatch.com/article/904345601-mhm-invests-237-5-million-to-create-a-healthier-future-across-south-texas Andorra Health Watch en PressRelease 2026-04-07T17:47:05+00:00 MHM Invests $237.5 Million to Create a Healthier Future Across South Texas https://ml.globenewswire.com/media/MjM4YmQ3ZDgtN2QzYy00MjdjLTk2ODQtNDllZjc1MjY2N2FiLTEyOTc4OTgtMjAyNi0wNC0wNy1lbg==/tiny/Methodist-Healthcare-Ministrie.png https://www.andorrahealthwatch.com/article/904345599-global-dna-read-write-and-edit-market-to-surge-to-67-7-billion-by-2030-driven-by-crispr-advances-genomic-diagnostics-and-expanding-clinical Andorra Health Watch en PressRelease 2026-04-07T17:44:41+00:00 Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.andorrahealthwatch.com/article/904345591-gluco-zen-drops-under-investigation-safety-concerns-arise-amid-researching-the-ingredients-side-effects-risk-for-glucozen Andorra Health Watch en PressRelease 2026-04-07T17:35:22+00:00 Gluco Zen Drops Under Investigation: Safety Concerns Arise Amid Researching the Ingredients' Side Effects Risk for GlucoZen https://zingfast.com/wp-content/uploads/2026/04/Gluco-Zen-Drops.jpg https://www.andorrahealthwatch.com/article/904345226-genfit-announces-publication-of-the-2025-universal-registration-document Andorra Health Watch en PressRelease 2026-04-07T17:30:00+00:00 GENFIT Announces Publication of the 2025 Universal Registration Document   https://ml-eu.globenewswire.com/media/YjA0MjRlZDQtMzQxZS00MDdhLTg3ZGEtZmVhOTQ4ZDQzZWI3LTEwMTEyNjgtMjAyNi0wNC0wNy1lbg==/tiny/GENFIT-S-A-.png https://www.andorrahealthwatch.com/article/904345280-genfit-mise-disposition-du-document-d-enregistrement-universel-2025 Andorra Health Watch en PressRelease 2026-04-07T17:30:00+00:00 GENFIT : Mise à disposition du Document d’Enregistrement Universel 2025   https://ml-eu.globenewswire.com/media/YjA0MjRlZDQtMzQxZS00MDdhLTg3ZGEtZmVhOTQ4ZDQzZWI3LTEwMTEyNjgtMjAyNi0wNC0wNy1mcg==/tiny/GENFIT-S-A-.png https://www.andorrahealthwatch.com/article/904345559-natural-remedies-awarded-american-botanical-council-s-2026-varro-e-tyler-commercial-investment-in-phytomedicinal-research-award Andorra Health Watch en PressRelease 2026-04-07T17:19:41+00:00 Natural Remedies Awarded American Botanical Council’s 2026 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award https://ml.globenewswire.com/media/afb640f0-73d1-4cd2-bcbe-9a80b381d7cc/medium/2026-abc-varro-e-tyler-commercial-investment-in-phytomedicin.jpg https://www.andorrahealthwatch.com/article/904336536-coeptis-announces-approval-of-z-squared-inc-s-nasdaq-listing-application Andorra Health Watch en PressRelease 2026-04-07T16:05:56+00:00 Coeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing Application https://ml.globenewswire.com/media/6ef667b8-3767-4031-9180-f4ba33c81938/small/coeptis-logo-final-rgb-300dpi-png.png https://www.andorrahealthwatch.com/article/904327021-heartfocus-and-inteleos-launch-first-ai-cardiac-pocus-certification Andorra Health Watch en PressRelease 2026-04-07T15:24:18+00:00 HeartFocus and Inteleos Launch First AI Cardiac POCUS Certification https://ml.globenewswire.com/media/NTFkODg1MzItY2Q4MC00MTY2LTk4NjItODc1OTc1OTA4YjUyLTEyNDUwMzItMjAyNi0wNC0wNy1lbg==/tiny/Inteleos-Inc-.png https://www.andorrahealthwatch.com/article/904326952-3-ways-pharmacists-can-help-maximize-your-glp-1-experience Andorra Health Watch en PressRelease 2026-04-07T15:01:15+00:00 3 Ways Pharmacists Can Help Maximize Your GLP-1 Experience https://ml.globenewswire.com/Resource/Download/f72143cc-6829-468e-aeb9-94a8dbdcb874/17866-1.jpg https://www.andorrahealthwatch.com/article/904318679-speke-ai-to-showcase-ambient-ai-solutions-at-uca-s-2026-urgent-care-convention Andorra Health Watch en PressRelease 2026-04-07T14:37:17+00:00 Speke AI to Showcase Ambient AI Solutions at UCA’s 2026 Urgent Care Convention https://ml.globenewswire.com/media/NTE3ZDRhZjgtMjgwNi00MGNkLThlOGItYmQwNzU4OTBiMDNkLTUwMDE1NDA4MS0yMDI2LTA0LTA3LWVu/tiny/Speke-AI.png https://www.andorrahealthwatch.com/article/904318654-nextel-medical-corp-announces-pivotal-milestone-in-commercial-launch-of-patent-protected-nanog-dna-cancer-screening-test Andorra Health Watch en PressRelease 2026-04-07T14:30:00+00:00 NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test https://ml.globenewswire.com/media/ZmQ2OTkwNDMtN2QzOS00OWQ1LThhYzctYzg5MzFjMjgwODMwLTUwMDE1ODM1Mi0yMDI2LTA0LTA3LWVu/tiny/Exousia-Pro-Inc-.png https://www.andorrahealthwatch.com/article/904318466-bioora-and-octane-biotech-sign-letter-of-intent-to-expand-cell-therapy-manufacturing-using-the-cocoon-platform Andorra Health Watch en PressRelease 2026-04-07T14:15:00+00:00 BioOra and Octane Biotech Sign Letter of Intent to Expand Cell Therapy Manufacturing Using the Cocoon® Platform https://ml.globenewswire.com/media/YzFhYmQ1NzYtNzA3My00Y2JiLWE2MGQtMjM3ZDBmYzMxNTJhLTEzMDQwMTAtMjAyNi0wNC0wNy1lbg==/tiny/Octane-Medical-Group.png https://www.andorrahealthwatch.com/article/904318295-regional-health-properties-reports-fourth-quarter-2025-results Andorra Health Watch en PressRelease 2026-04-07T14:05:00+00:00 Regional Health Properties Reports Fourth Quarter 2025 Results https://ml.globenewswire.com/media/bfd51062-4a60-4cf0-9f2f-a4b109b52e4a/small/logo-jpg.jpg https://www.andorrahealthwatch.com/article/904318008-folia-health-launches-app-based-study-to-unlock-novel-real-world-evidence-of-symptom-burden-and-unmet-need-for-patients-and-caregivers-in-cidp Andorra Health Watch en PressRelease 2026-04-07T14:00:00+00:00 Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP https://ml.globenewswire.com/media/858e11f4-96a0-4321-93eb-d278df849ccf/small/untitled-design-1-png.png https://www.andorrahealthwatch.com/article/904318126-inc-recognizes-u-s-oral-surgery-management-for-growth Andorra Health Watch en PressRelease 2026-04-07T13:41:00+00:00 Inc. Recognizes U.S. Oral Surgery Management for Growth https://ml.globenewswire.com/media/9472c27c-8b6d-4c87-95fd-31f1f0140263/small/usosm-logo-png.png https://www.andorrahealthwatch.com/article/904310228-merakris-therapeutics-provides-fda-update-and-reports-interim-findings-for-mtx-001-in-venous-leg-ulcers Andorra Health Watch en PressRelease 2026-04-07T13:30:00+00:00 Merakris Therapeutics Provides FDA Update and Reports Interim Findings for MTX-001 in Venous Leg Ulcers https://ml.globenewswire.com/media/5b9c5fed-3332-4d4d-b8b6-6ab1b15faaed/small/mrks-brand-logo-final-fullcolor-png.png https://www.andorrahealthwatch.com/article/904310391-nurexone-biologic-s-u-s-subsidiary-exo-top-and-florida-based-bioxtek-sign-strategic-loi-for-exosome-manufacturing-and-commercialization Andorra Health Watch en PressRelease 2026-04-07T13:18:00+00:00 NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization https://ml.globenewswire.com/media/1514c671-cc84-4bcb-82d7-b834fce40882/small/nurexone-logo-rebrand-large-png.png https://www.andorrahealthwatch.com/article/904308717-cellution-biologics-inc-announces-official-entry-into-the-ocular-market-at-ascrs-with-the-launch-of-opticover Andorra Health Watch en PressRelease 2026-04-07T13:11:00+00:00 Cellution Biologics Inc. Announces Official Entry into the Ocular Market at ASCRS with the Launch of OptiCover™ https://ml.globenewswire.com/media/10957e60-6696-483a-9df0-88f8713da811/medium/opticover.jpg https://www.andorrahealthwatch.com/article/904309254-srx-health-solutions-returns-5-69-in-march-2026-driven-by-emjx-artificial-intelligence-ai-engine Andorra Health Watch en PressRelease 2026-04-07T13:05:00+00:00 SRx Health Solutions Returns +5.69% in March 2026 Driven by EMJX Artificial Intelligence (AI) Engine https://ml.globenewswire.com/media/768807fe-a29b-48f5-be44-977c8eaf49f0/small/srxlogo-jpg.jpg https://www.andorrahealthwatch.com/article/904310171-medx-holdings-reports-strong-q4-results-achieves-net-profitability-and-announces-strategic-partnerships-to-supercharge-franchise-expansion Andorra Health Watch en PressRelease 2026-04-07T13:05:00+00:00 MEDX HOLDINGS REPORTS STRONG Q4 RESULTS, ACHIEVES NET PROFITABILITY, AND ANNOUNCES STRATEGIC PARTNERSHIPS TO SUPERCHARGE FRANCHISE EXPANSION https://ml.globenewswire.com/media/995733cb-620f-4ea6-b204-8b5b5689df30/small/medx-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904310583-treace-announces-first-surgical-cases-with-the-superbite-compression-screw-system Andorra Health Watch en PressRelease 2026-04-07T13:04:29+00:00 Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System https://ml.globenewswire.com/media/6f3a2631-2457-4100-950a-3dec602ec68d/medium/superbite-compression-screw-system.png https://www.andorrahealthwatch.com/article/904308778-saladax-biomedical-to-expand-international-access-to-drug-level-testing-for-psychiatry-and-oncology Andorra Health Watch en PressRelease 2026-04-07T13:00:00+00:00 Saladax Biomedical to Expand International Access to Drug Level Testing for Psychiatry and Oncology https://ml.globenewswire.com/media/M2NiMWYwYzAtNjA1My00OWFiLWFkN2ItZjY5YzgxNjE4MzI3LTUwMDEyNDYwOC0yMDI2LTA0LTA3LWVu/tiny/Saladax-Biomedical-Inc-.png https://www.andorrahealthwatch.com/article/904308956-pathai-and-medstar-health-announce-partnership-to-deploy-the-aisight-dx-digital-pathology-platform-and-advanced-ai-applications Andorra Health Watch en PressRelease 2026-04-07T13:00:00+00:00 PathAI and MedStar Health Announce Partnership to Deploy the AISight® Dx Digital Pathology Platform and Advanced AI Applications https://ml.globenewswire.com/media/ab2bfc12-ae80-47c6-9345-a98783489ed7/small/pathai-logo-standard-png.png https://www.andorrahealthwatch.com/article/904309046-death-by-a-thousand-vendors-81-of-employers-are-hiring-just-to-keep-up-with-digital-health-vendor-sprawl Andorra Health Watch en PressRelease 2026-04-07T13:00:00+00:00 Death by a Thousand Vendors: 81% of Employers Are Hiring Just to Keep Up with Digital Health Vendor Sprawl https://ml.globenewswire.com/media/b8d88974-2aeb-4baa-ad3b-2ab758ed4dd9/small/solera-main-logo-red-png.png https://www.andorrahealthwatch.com/article/904309197-lumin-health-appoints-matthew-mosquera-md-ms-as-regional-medical-director-and-site-director-of-lumin-cambridge Andorra Health Watch en PressRelease 2026-04-07T13:00:00+00:00 Lumin Health Appoints Matthew Mosquera, MD, MS, as Regional Medical Director and Site Director of Lumin Cambridge https://ml.globenewswire.com/media/cb31fc23-dea3-476e-971b-6265973b0739/medium/matthew-mosquera.jpeg https://www.andorrahealthwatch.com/article/904310148-ai-and-online-health-information-are-booming-but-americans-don-t-fully-trust-what-they-find Andorra Health Watch en PressRelease 2026-04-07T13:00:00+00:00 AI and Online Health Information Are Booming, But Americans Don’t Fully Trust What They Find https://ml.globenewswire.com/media/NjE3YzhiYjItN2E5Yy00MjE5LWI1YTQtMGUzMmVlZjY3NzM2LTUwMDE2MDA3Mi0yMDI2LTA0LTA3LWVu/tiny/American-Association-of-Nurse-.png https://www.andorrahealthwatch.com/article/904309350-outlook-therapeutics-announces-formal-dispute-resolution-request-for-ons-5010-lytenava-bevacizumab-vikg-accepted-by-fda Andorra Health Watch en PressRelease 2026-04-07T12:50:00+00:00 Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA https://ml.globenewswire.com/media/cbff3302-f8d2-466a-beff-8c33252f9c70/small/otlk-png.png https://www.andorrahealthwatch.com/article/904309225-vivos-therapeutics-completes-private-placement-with-existing-private-equity-investor-new-seneca-partners Andorra Health Watch en PressRelease 2026-04-07T12:45:00+00:00 Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners https://ml.globenewswire.com/media/22d07f60-2e17-421d-bbc3-748c2402061e/small/picture2-jpg.JPG https://www.andorrahealthwatch.com/article/904308798-moleculin-releases-next-ceo-corner-segment-highlighting-annamycin-s-non-cardiotoxic-profile Andorra Health Watch en PressRelease 2026-04-07T12:36:00+00:00 Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile https://ml.globenewswire.com/media/7fa09722-2ef8-49fc-bc24-6b150093f8ba/small/mbrx-logo-png.png https://www.andorrahealthwatch.com/article/904299971-20-20-biolabs-selected-by-evexia-diagnostics-to-offer-onetest-for-cancer-through-evexia-platform Andorra Health Watch en PressRelease 2026-04-07T12:31:00+00:00 20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform https://ml.globenewswire.com/media/bcaf95ca-9983-408c-bc61-646e4ee2f925/small/2020-biolabs-logo-png.png https://www.andorrahealthwatch.com/article/904299756-xenon-to-highlight-phase-3-x-tole2-long-term-data-for-azetukalner-in-focal-onset-seizures-at-2026-aan-annual-meeting Andorra Health Watch en PressRelease 2026-04-07T12:30:00+00:00 Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting https://ml.globenewswire.com/media/505b89d3-dfd1-46e8-bc3b-3c9c699ef7ec/small/xenon-logo-tm-full-color-250x80px-png.png https://www.andorrahealthwatch.com/article/904299796-abeona-therapeutics-announces-appointment-of-keith-a-goldan-to-its-board-of-directors Andorra Health Watch en PressRelease 2026-04-07T12:30:00+00:00 Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors https://ml.globenewswire.com/media/f11f9f14-9744-4666-aef3-9771488c41bd/small/thumb-1740-12-silhouette-vertical-full-color-png.png https://www.andorrahealthwatch.com/article/904299918-clover-health-empowers-members-to-take-charge-of-their-health-data-through-healthex-partnership Andorra Health Watch en PressRelease 2026-04-07T12:30:00+00:00 Clover Health Empowers Members to Take Charge of Their Health Data Through HealthEx Partnership https://ml.globenewswire.com/media/1a48a25b-b654-4d62-adb3-d1a776346264/small/clover-logo-green-rgb-jpg.jpg https://www.andorrahealthwatch.com/article/904299951-integra-lifesciences-unveils-new-real-world-evidence-highlighting-primatrix-utilization Andorra Health Watch en PressRelease 2026-04-07T12:30:00+00:00 Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix® Utilization https://ml.globenewswire.com/media/00cf1e29-7492-4f89-bab1-6691cf2253c4/medium/primatrix-dermal-scaffold.png https://www.andorrahealthwatch.com/article/904299992-ss-innovations-to-host-smrsc-2026-in-new-delhi-india-from-april-9-11-2026 Andorra Health Watch en PressRelease 2026-04-07T12:30:00+00:00 SS Innovations to Host SMRSC 2026 in New Delhi, India from April 9-11, 2026 https://ml.globenewswire.com/media/cef267e0-040f-4889-a706-cc4d0ae49e55/small/new-logo-april-23-2025-png.png https://www.andorrahealthwatch.com/article/904300074-cormedix-to-participate-in-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-07T12:30:00+00:00 CorMedix to Participate in Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/a14d732c-3f66-4a3c-96bb-7fc8ba5797bb/small/crmd-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904300165-milestone-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-07T12:30:00+00:00 Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/49b2e16b-2deb-4c9e-9c20-6cc4fd6c15ab/small/milestone-pharmaceuticals-logo-png.png https://www.andorrahealthwatch.com/article/904300233-cdt-notes-sarborg-publication-of-prism-framework-expanding-ai Andorra Health Watch en PressRelease 2026-04-07T12:30:00+00:00 CDT Notes Sarborg Publication of PRISM Framework Expanding AI https://ml.globenewswire.com/media/MjNiMmZlYjctZjk3NS00MWViLThkMjktZWUwZGQ1YzVkNzRjLTEyNzQxMDItMjAyNi0wNC0wNy1lbg==/tiny/CDT-Equity-Inc-.png https://www.andorrahealthwatch.com/article/904299831-biorestorative-therapies-announces-strategic-collaboration-with-203-creates-to-build-and-commercialize-biocosmeceutical-platform Andorra Health Watch en PressRelease 2026-04-07T12:15:00+00:00 BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform https://ml.globenewswire.com/media/a9a09a16-9f91-466d-a0b4-2a7f2fd05ebe/small/logo-png.png https://www.andorrahealthwatch.com/article/904299713-nextcure-receives-fast-track-designation-for-sim0505-cdh6-adc-in-ovarian-cancer Andorra Health Watch en PressRelease 2026-04-07T12:05:00+00:00 NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer https://ml.globenewswire.com/media/df24cd65-0f3d-4ede-9e7a-c3f58ce6e9d4/small/logo-nextcure-jpg.jpg https://www.andorrahealthwatch.com/article/904300472-emergent-biosolutions-launches-new-narcan-nasal-spray-carrying-case-and-multipacks-alongside-college-campus-outreach-to-expand-opioid-overdose Andorra Health Watch en PressRelease 2026-04-07T12:05:00+00:00 Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness https://ml.globenewswire.com/media/3fcbfc65-93d7-475f-9f23-b47fbf2ab8ca/medium/narcan-nasal-spray-multipacks.png https://www.andorrahealthwatch.com/article/904299511-evaxion-announces-last-patient-visit-in-one-year-extension-of-phase-2-trial-with-personalized-cancer-vaccine-evx-01 Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 https://ml-eu.globenewswire.com/media/19d0d69c-7f37-4d3b-8f26-2866d4ec3311/small/evaxion-deepblue-rgb-png.png https://www.andorrahealthwatch.com/article/904299601-lyell-immunopharma-announces-participation-in-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/fa4a7bb1-f8ea-45e7-ba51-37077689a4fb/small/lyell-branding-color-rgb-102918a-copy-jpg.jpg https://www.andorrahealthwatch.com/article/904299705-inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension https://ml.globenewswire.com/media/32b8d8bc-ebf8-43c0-866a-6613b22263b1/small/ikt-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904299752-amneal-announces-2-million-donation-to-support-patient-access-to-essential-medicines-during-parkinson-s-awareness-month Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month https://ml.globenewswire.com/media/a20d6f40-90af-422f-ab14-47208fdbad2f/small/amneal-rgb-k-png.png https://www.andorrahealthwatch.com/article/904299830-crispr-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/5dac7d0d-131d-4047-bab7-db8e0719bf58/small/crispr-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904299833-gatc-health-and-uc-irvine-announce-landmark-pnas-publication-validating-ai-platform-for-opioid-use-disorder-treatment Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 GATC Health and UC Irvine Announce Landmark PNAS Publication Validating AI-Platform for Opioid Use Disorder Treatment https://ml.globenewswire.com/media/8252f5cc-6aca-4b39-b708-845c0ce98b86/small/color-logo-vector-png.png https://www.andorrahealthwatch.com/article/904299835-solid-biosciences-to-participate-at-upcoming-investor-conferences Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Solid Biosciences to Participate at Upcoming Investor Conferences https://ml.globenewswire.com/media/bb5e6b30-d9d9-464f-8c64-33a09eacc3fb/small/solid-1029x579-png.png https://www.andorrahealthwatch.com/article/904299849-valitor-announces-oral-presentation-at-the-upcoming-association-for-research-in-vision-and-ophthalmology-arvo-2026-annual-meeting Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Valitor Announces Oral Presentation at the Upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting https://ml.globenewswire.com/media/58da3c80-c616-4358-9bbe-2936ace96649/small/valitor-sidebyside-png.png https://www.andorrahealthwatch.com/article/904299853-route-92-medical-announces-50-million-growth-financing Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Route 92 Medical Announces $50 Million Growth Financing https://ml.globenewswire.com/media/526036da-ddbe-4a9a-9222-9570f7cd6544/small/r-rt92-logo-rbg0-png.png https://www.andorrahealthwatch.com/article/904299871-akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.andorrahealthwatch.com/article/904299961-aclarion-highlights-growing-adoption-of-nociscan-at-the-london-clinic-with-new-physician-video Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png https://www.andorrahealthwatch.com/article/904300025-calidi-biotherapeutics-announces-speaker-presentation-at-asgct-conference-in-boston-on-may-14-2026-highlighting-the-redtail-platform-s-ability-to Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://www.andorrahealthwatch.com/article/904300073-corbus-pharmaceuticals-announces-broad-alignment-with-fda-on-registration-path-for-crb-701-in-second-line-hnscc-and-cervical-cancer Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer https://ml.globenewswire.com/media/459d6fb1-b336-4d47-8aa1-f9198bda891d/small/corbus-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904300089-liquidia-corporation-to-participate-in-upcoming-investor-conferences Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Liquidia Corporation to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/f7659070-cc55-4e68-ae70-33013e7df72c/small/liquidia-new-logo-png.png https://www.andorrahealthwatch.com/article/904300151-electrocore-announces-first-patient-enrollment-in-investigator-led-study-of-gammacore-nvns-for-ptsd Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD https://ml.globenewswire.com/media/b80ed5b6-a449-461c-9034-85386286b09d/small/ec-logo-2018-tm-cmyk-jpg.jpg https://www.andorrahealthwatch.com/article/904300354-jupiter-neurosciences-appoints-kristopher-fishman-and-sanjiv-lal-to-nugevia-advisory-board Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board https://ml.globenewswire.com/media/4e829d7e-ecf6-46ad-98fe-479755d626e1/small/image-png.png https://www.andorrahealthwatch.com/article/904300403-polyrizon-ltd-announces-3-5-million-registered-direct-offering-and-private-placement Andorra Health Watch en PressRelease 2026-04-07T12:00:00+00:00 Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement https://ml.globenewswire.com/media/N2M3NTE1MmItYWFmMi00MDNlLWE4MTItMWIxMDg4MWYwMTRlLTUwMDEyOTIyMy0yMDI2LTA0LTA3LWVu/tiny/Polyrizon-Ltd-.png https://www.andorrahealthwatch.com/article/904300175-artelo-biosciences-regains-compliance-with-nasdaq-listing-requirements Andorra Health Watch en PressRelease 2026-04-07T11:50:00+00:00 Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements https://ml.globenewswire.com/media/460502d7-b0d3-43d8-a15a-5b2bb963bbbb/small/artelo-jpg.jpg https://www.andorrahealthwatch.com/article/904299627-marvel-biosciences-secures-financial-and-strategic-investment-with-5-horizon-ventures Andorra Health Watch en PressRelease 2026-04-07T11:30:00+00:00 Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures https://ml.globenewswire.com/media/d49e32dc-88d9-4694-a3dd-6e663548e80d/small/picture1-png.png https://www.andorrahealthwatch.com/article/904299632-anavex-life-sciences-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-07T11:30:00+00:00 Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/1b0f858f-4f7f-4f50-b691-a25307283fb5/small/anavexlogor-transparent-3x-png.png https://www.andorrahealthwatch.com/article/904299759-everbright-health-announces-ai-enabled-platform-to-unlock-access-to-advanced-mental-health-interventions Andorra Health Watch en PressRelease 2026-04-07T11:30:00+00:00 Everbright Health Announces AI-Enabled Platform to Unlock Access to Advanced Mental Health Interventions https://ml.globenewswire.com/media/2ce4a623-23ed-4e51-9115-db1f2526bcfc/small/everbrighthealth-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904299841-plus-therapeutics-receives-ama-pla-code-for-cnside-csf-tumor-cell-enumeration-test-advancing-reimbursement-and-u-s-commercial-adoption Andorra Health Watch en PressRelease 2026-04-07T11:30:00+00:00 Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption https://ml.globenewswire.com/media/92d7aa70-e37d-4870-bccf-d83b68ba5612/small/plus-logo-png.png https://www.andorrahealthwatch.com/article/904299993-cognition-therapeutics-to-present-at-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-07T11:30:00+00:00 Cognition Therapeutics to Present at Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/a14fd627-7ccb-45e2-95fe-792bbfb83231/small/2020-0227-cognition-logo-for-gnw-png.png https://www.andorrahealthwatch.com/article/904300070-palvella-therapeutics-appoints-accomplished-commercial-leader-kent-taylor-as-senior-vice-president-of-sales Andorra Health Watch en PressRelease 2026-04-07T11:30:00+00:00 Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales https://ml.globenewswire.com/media/83fd569b-5e6c-46ad-882a-6430f8ab755a/small/palvella-2025-logo-new-jpg.jpg https://www.andorrahealthwatch.com/article/904300109-cervomed-to-provide-neflamapimod-clinical-program-update-and-participate-in-a-panel-on-biomarkers-at-2026-lewy-body-dementia-association-annual Andorra Health Watch en PressRelease 2026-04-07T11:30:00+00:00 CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting https://ml.globenewswire.com/media/332fd58e-5e2b-4c96-8eaf-719ac2e34f52/small/cervomed-logo-png.png https://www.andorrahealthwatch.com/article/904300157-nervgen-pharma-announces-successful-end-of-phase-2-meeting-and-fda-alignment-on-restore-a-phase-3-registrational-study-of-nvg-291-for-chronic Andorra Health Watch en PressRelease 2026-04-07T11:30:00+00:00 NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png https://www.andorrahealthwatch.com/article/904300328-weight-watchers-appoints-lisa-gavales-and-sue-gove-to-board-of-directors Andorra Health Watch en PressRelease 2026-04-07T11:30:00+00:00 Weight Watchers Appoints Lisa Gavales and Sue Gove to Board of Directors https://ml.globenewswire.com/media/f435b439-7f75-4d2f-a6cc-0e4e2ed811ea/small/weightwatchers-wordmark-boldblue-png.png https://www.andorrahealthwatch.com/article/904290412-pluristyx-extends-patent-portfolio-in-universal-cell-therapy-with-new-u-s-patent-for-iact-stealth-technology Andorra Health Watch en PressRelease 2026-04-07T11:09:00+00:00 Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology https://ml.globenewswire.com/media/22e38345-b052-4cc3-a4c3-556e798109f3/small/pluristyx-logo-blue-apr22-png.png https://www.andorrahealthwatch.com/article/904290254-fennec-pharmaceuticals-announces-investigator-sponsored-study-to-be-conducted-by-university-of-arizona-cancer-center Andorra Health Watch en PressRelease 2026-04-07T11:03:00+00:00 Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center https://ml.globenewswire.com/media/2eeb9b85-0beb-4bbe-a7af-1c0e9403db44/small/fennec-logo-png.png https://www.andorrahealthwatch.com/article/904290176-invivyd-launches-antibodies-for-any-body-in-partnership-with-world-champion-skier-lindsey-vonn-to-inspire-actions-that-help-support-immune-health Andorra Health Watch en PressRelease 2026-04-07T11:01:00+00:00 Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health https://ml.globenewswire.com/media/7bf12f50-1073-4ce7-81ac-89426c07add3/small/untitled-design-2-png.png https://www.andorrahealthwatch.com/article/904290028-ac-immune-announces-amendment-to-morphomer-tau-license-and-collaboration-agreement-with-lilly Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg https://www.andorrahealthwatch.com/article/904290055-mediwound-to-present-new-escharex-data-at-leading-wound-care-conferences Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 MediWound to Present New EscharEx® Data at Leading Wound Care Conferences https://ml.globenewswire.com/media/55509183-b8b9-4da4-ae63-92c83760b5d9/small/mdwd-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904290057-radiopharm-theranostics-and-siemens-healthineers-sign-clinical-supply-agreement-for-rad101-in-the-u-s Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. https://ml-eu.globenewswire.com/media/8e246920-183e-46a4-b13c-a3c9ec50ada9/small/radx-logo-png.png https://www.andorrahealthwatch.com/article/904290245-sionna-therapeutics-to-participate-in-the-raymond-james-2026-biotech-innovation-symposium Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium https://ml.globenewswire.com/media/0cda8c25-e758-4f0d-86f2-875df8411a9a/small/sionna-png.png https://www.andorrahealthwatch.com/article/904290255-soleo-health-relocates-denver-specialty-pharmacy-to-support-continued-growth Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 Soleo Health Relocates Denver Specialty Pharmacy to Support Continued Growth https://ml.globenewswire.com/media/b3c4bcdc-fa25-4f50-8b81-09f13e80a008/small/soleo-logo-1024-x-1024-png.png https://www.andorrahealthwatch.com/article/904290282-breckenridge-distillery-introduces-honey-whiskey-crafted-with-rare-nigerian-goldswarm-honey-a-must-try-for-whiskey-enthusiasts Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 Breckenridge Distillery Introduces Honey Whiskey Crafted with Rare Nigerian Goldswarm Honey—A Must-Try for Whiskey Enthusiasts https://ml.globenewswire.com/media/cb623008-0c9a-49db-ab38-6e3062dd8bdb/medium/breckenridge-distillery-honey-whiskey.jpg https://www.andorrahealthwatch.com/article/904290354-climb-bio-announces-fda-fast-track-designation-for-budoprutug-for-the-treatment-of-primary-membranous-nephropathy Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy https://ml.globenewswire.com/media/2a42b557-6e44-4818-bfce-2238a05f2c43/small/climb-400x400-002-jpg.jpg https://www.andorrahealthwatch.com/article/904290361-skye-bioscience-presenting-at-glp-1-based-therapeutics-summit Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit https://ml.globenewswire.com/media/905e06d8-af43-4f7a-b097-8c12ce1d3aa0/small/skye-darkblue-jpg.jpg https://www.andorrahealthwatch.com/article/904290381-nurix-therapeutics-to-participate-in-upcoming-investor-conference Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 Nurix Therapeutics to Participate in Upcoming Investor Conference https://ml.globenewswire.com/media/65f50366-0a4e-4329-b0f5-f737c6145524/small/new-primary-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904290410-fortrea-unveils-fortrea-intelligent-technology-to-help-sponsors-and-sites-run-smarter-more-integrated-trials Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials https://ml.globenewswire.com/media/9fbbe00b-8782-464e-83e6-5843c563884a/small/fortrea-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904290597-neuronetics-comments-on-letter-from-pointillist-family-office Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 Neuronetics Comments on Letter from Pointillist Family Office https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png https://www.andorrahealthwatch.com/article/904290600-okyo-pharma-announces-scientific-advisory-board-meeting-and-urcosimod-data-presentation-during-ascrs-annual-meeting Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting https://ml.globenewswire.com/media/23e4046d-dcf9-4dd1-945e-461e98a27d15/small/full-logo-okyo-jpg.jpg https://www.andorrahealthwatch.com/article/904290602-vantage-hemp-co-engages-acos-and-gpos-to-advance-participation-in-cms-cbd-pilot-program Andorra Health Watch en PressRelease 2026-04-07T11:00:00+00:00 Vantage Hemp Co. Engages ACOs and GPOs to Advance Participation in CMS CBD Pilot Program https://ml.globenewswire.com/media/d38e4562-945b-4df7-8869-623c43be10f1/medium/inside-vantages-manufacturing-facility.jpg https://www.andorrahealthwatch.com/article/904290206-ani-pharmaceuticals-announces-publication-of-new-day-clinical-trial-results-in-ophthalmology Andorra Health Watch en PressRelease 2026-04-07T10:50:00+00:00 ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png https://www.andorrahealthwatch.com/article/904290397-bluejay-diagnostics-inc-announces-completion-of-624-patient-enrollments-in-symon-ii-pivotal-clinical-trial Andorra Health Watch en PressRelease 2026-04-07T10:30:00+00:00 Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial https://ml.globenewswire.com/media/d0d4a766-5115-448d-ba8a-d522100949f1/small/bjdx-jpg.jpg https://www.andorrahealthwatch.com/article/904280802-serina-therapeutics-to-present-at-the-5th-lnp-formulation-process-development-summit Andorra Health Watch en PressRelease 2026-04-07T10:00:00+00:00 Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit https://ml.globenewswire.com/media/7f8e4304-8465-4d4d-a7e3-ebc4eae51f29/small/yellow-burts-blue-text-1-png.png https://www.andorrahealthwatch.com/article/904280810-ascellahealth-named-to-financial-times-americas-fastest-growing-companies-2026-list Andorra Health Watch en PressRelease 2026-04-07T10:00:00+00:00 AscellaHealth Named to Financial Times Americas’ Fastest Growing Companies 2026 List https://ml.globenewswire.com/media/5278c55f-330c-41a1-8446-d8b1a07bbc55/small/ah-logo-colornotag-4x-png.png https://www.andorrahealthwatch.com/article/904280821-greenwich-lifesciences-provides-update-on-patent-claims-potentially-doubling-gp2-market-potential Andorra Health Watch en PressRelease 2026-04-07T10:00:00+00:00 Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg https://www.andorrahealthwatch.com/article/904263002-oculis-to-participate-in-upcoming-investor-conferences Andorra Health Watch en PressRelease 2026-04-07T08:00:00+00:00 Oculis to Participate in Upcoming Investor Conferences https://ml-eu.globenewswire.com/media/f6fa6e90-83a4-4baa-a3b6-5483017d26b9/small/oculis-logo-gradient-jpg-resized-jpg.jpg https://www.andorrahealthwatch.com/article/904253341-sononeu-exits-stealth-as-key-part-of-us-government-funded-research-program-worth-up-to-41-3m-to-advance-sonogenetics-into-clinic Andorra Health Watch en PressRelease 2026-04-07T07:00:00+00:00 SonoNeu exits stealth as key part of US Government-funded research program worth up to $41.3m to advance sonogenetics into clinic https://ml-eu.globenewswire.com/media/28b90f6b-ca31-4be4-92ca-1d1e341f55f3/small/sononeu-small-logo-png.png https://www.andorrahealthwatch.com/article/904235360-press-release-sanofi-s-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-in-asthma-and-crswnp Andorra Health Watch en PressRelease 2026-04-07T05:00:00+00:00 Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904235375-communiqu-de-presse-le-lunsekimig-de-sanofi-a-atteint-les-crit-res-d-valuation-principal-et-secondaires-cl-s-dans-les-tudes-respiratoires-de-phase Andorra Health Watch en PressRelease 2026-04-07T05:00:00+00:00 Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904203057-memogenesis-claims-evaluated-researching-the-latest-memo-genesis-formulation-facts Andorra Health Watch en PressRelease 2026-04-07T01:10:16+00:00 MemoGenesis Claims Evaluated: Researching the Latest Memo Genesis Formulation Facts https://zingfast.com/wp-content/uploads/2026/04/MemoGenesis.jpg https://www.andorrahealthwatch.com/article/904203030-ryoncil-continues-successful-first-year-launch-with-net-sales-of-us-30-3m-in-march-quarter Andorra Health Watch en PressRelease 2026-04-07T01:03:58+00:00 Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter https://ml.globenewswire.com/media/a9938a8a-a0ba-4708-abd5-2219515343fc/small/mesologo-png.png https://www.andorrahealthwatch.com/article/904187967-q1-2026-strong-revenue-growth-and-therapeutics-pipeline-advancement Andorra Health Watch en PressRelease 2026-04-06T23:37:15+00:00 Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.andorrahealthwatch.com/article/904187944-organogenesis-achieves-primary-endpoint-in-randomized-controlled-trial-of-puraply-am Andorra Health Watch en PressRelease 2026-04-06T23:02:29+00:00 Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM https://ml.globenewswire.com/media/9c2f551f-b7b2-403a-bf43-78f1889401e5/small/organogenesis-jpg.jpg https://www.andorrahealthwatch.com/article/904174110-renovare-therapeutics-inc-announces-company-launch-and-collaboration-with-cu-boulder-awardee-of-up-to-33-5-million-in-arpa-h-funding-to-advance Andorra Health Watch en PressRelease 2026-04-06T21:59:37+00:00 Renovare Therapeutics, Inc. Announces Company Launch and Collaboration with CU Boulder Awardee of up to $33.5 Million in ARPA-H Funding to Advance Osteoarthritis Regenerative Therapies https://ml.globenewswire.com/media/OTA0OGZiNjgtYTYzNi00MDUzLTk4YmYtYTMwMzBjYjVjMmNmLTEzMjIzODItMjAyNi0wNC0wNi1lbg==/tiny/Renovare-Therapeutics-Inc-.png https://www.andorrahealthwatch.com/article/904173827-avicanna-announces-changes-to-its-board-of-directors Andorra Health Watch en PressRelease 2026-04-06T21:30:00+00:00 Avicanna Announces Changes to its Board of Directors https://ml.globenewswire.com/media/c9abc2f4-efdc-40f6-921d-a5da048eda46/small/avicanna-logo-colour-withtm-01-png.png https://www.andorrahealthwatch.com/article/904173889-organogenesis-announces-successful-fda-meeting-and-plan-to-file-bla-for-renu-for-knee-osteoarthritis-pain Andorra Health Watch en PressRelease 2026-04-06T21:30:00+00:00 Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain https://ml.globenewswire.com/media/9c2f551f-b7b2-403a-bf43-78f1889401e5/small/organogenesis-jpg.jpg https://www.andorrahealthwatch.com/article/904167591-metabo-drops-claims-evaluated-recent-investigation-into-metabodrops-official-website-announcement Andorra Health Watch en PressRelease 2026-04-06T21:16:34+00:00 Metabo Drops Claims Evaluated: Recent Investigation Into MetaboDrops Official Website Announcement https://zingfast.com/wp-content/uploads/2026/04/Metabo-Drops.jpg https://www.andorrahealthwatch.com/article/904161943-neuronetics-announces-chief-financial-officer-transition Andorra Health Watch en PressRelease 2026-04-06T20:30:00+00:00 Neuronetics Announces Chief Financial Officer Transition https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png https://www.andorrahealthwatch.com/article/904162001-glyco-harmony-drops-claims-evaluated-explore-the-official-gluco-harmony-glycogen-support-website-facts Andorra Health Watch en PressRelease 2026-04-06T20:21:12+00:00 Glyco Harmony Drops Claims Evaluated: Explore the Official Gluco Harmony Glycogen Support Website Facts https://zingfast.com/wp-content/uploads/2026/04/Glyco-Harmony-Drops.jpg https://www.andorrahealthwatch.com/article/904161867-silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy Andorra Health Watch en PressRelease 2026-04-06T20:15:00+00:00 Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy https://ml.globenewswire.com/media/3b635464-4382-4b8b-8175-39cc32e08050/small/logo-png.png https://www.andorrahealthwatch.com/article/904161146-outset-medical-names-derick-elliott-as-executive-vice-president-of-commercial Andorra Health Watch en PressRelease 2026-04-06T20:05:00+00:00 Outset Medical Names Derick Elliott as Executive Vice President of Commercial https://ml.globenewswire.com/media/28778c78-03f1-4b17-9c13-3cc578c924dc/small/outset-id-orangegrey-png.png https://www.andorrahealthwatch.com/article/904161822-nanox-to-report-fourth-quarter-2025-financial-results-on-april-20-2026 Andorra Health Watch en PressRelease 2026-04-06T20:05:00+00:00 Nanox to Report Fourth Quarter 2025 Financial Results on April 20, 2026 https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg https://www.andorrahealthwatch.com/article/904161913-immuneering-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-06T20:05:00+00:00 Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/81d0c83f-ae53-4d6e-9c5e-d6963e02f29d/small/immuneering-logo-cropped-1-jpg.jpg https://www.andorrahealthwatch.com/article/904161866-dianthus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Andorra Health Watch en PressRelease 2026-04-06T20:01:00+00:00 Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/c9002285-2240-4dab-aced-77296f86a3fa/small/dianthus-logo-primary-full-color-cmyk-png.png https://www.andorrahealthwatch.com/article/904161983-ascendis-receives-orphan-drug-exclusivity-and-launches-yuviwel-navepegritide-in-the-united-states Andorra Health Watch en PressRelease 2026-04-06T20:01:00+00:00 Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States https://ml.globenewswire.com/media/b4b7c29a-478e-4a8e-b23b-b6a1cb18aee8/small/ascendis-final-logo-7-23-15-png.png https://www.andorrahealthwatch.com/article/904161906-cytokinetics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-06T20:00:00+00:00 Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/52e2be9f-e9e3-43af-a747-123fdcac4253/small/cytokinetics-png.png https://www.andorrahealthwatch.com/article/904149403-mistr-founder-tristan-schukraft-joins-the-producing-team-of-titanique Andorra Health Watch en PressRelease 2026-04-06T19:00:00+00:00 MISTR Founder Tristan Schukraft Joins the Producing Team of Titanique https://ml.globenewswire.com/media/NjA1ZGExYWItMDMwMC00NGI5LTk1ZTItM2NjNmIzZWNjZmNjLTUwMDEzNDg1Ny0yMDI2LTA0LTA2LWVu/tiny/MISTR.png https://www.andorrahealthwatch.com/article/904149512-glucozen-claim-evaluated-highly-effective-blood-sugar-support-for-natural-glucose-harmony Andorra Health Watch en PressRelease 2026-04-06T18:40:44+00:00 GlucoZen Claim Evaluated: Highly-Effective Blood Sugar Support for Natural Glucose Harmony https://zingfast.com/wp-content/uploads/2026/04/GlucoZen-Drops.jpg https://www.andorrahealthwatch.com/article/904143857-global-validation-calibration-and-standardization-in-life-sciences-market-to-reach-3-9-billion-by-2030-fueled-by-regulatory-demands-and-digital Andorra Health Watch en PressRelease 2026-04-06T18:00:00+00:00 Global Validation, Calibration and Standardization in Life Sciences Market to Reach $3.9 Billion by 2030, Fueled by Regulatory Demands and Digital Transformation https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.andorrahealthwatch.com/article/904143771-wellspan-health-announces-president-ceo-roxanna-gapstur-s-planned-retirement Andorra Health Watch en PressRelease 2026-04-06T17:49:26+00:00 WellSpan Health announces President & CEO Roxanna Gapstur’s planned retirement https://ml.globenewswire.com/media/NGE2MDdiZGQtMzEyMy00NmIxLWE0ZTUtM2JmODBmOTQyOTg1LTEyMjE1MzQtMjAyNi0wNC0wNi1lbg==/tiny/WellSpan-Health.png https://www.andorrahealthwatch.com/article/904138873-dibs-ai-unveils-version-9-0-platform-suite-to-streamline-orthodontic-workflows Andorra Health Watch en PressRelease 2026-04-06T17:30:00+00:00 DIBS AI Unveils Version 9.0 Platform Suite to Streamline Orthodontic Workflows https://ml.globenewswire.com/media/NzhmMTE3NzktZTQ1MS00OWY2LTkzMDgtZjAzYmU3OTY3YWI2LTEyMTI1MjAtMjAyNi0wNC0wNi1lbg==/tiny/OrthoSelect.png https://www.andorrahealthwatch.com/article/904129544-mistr-covers-florida-patients-as-adap-changes-create-gaps-in-hiv-treatment-access Andorra Health Watch en PressRelease 2026-04-06T16:14:44+00:00 MISTR Covers Florida Patients as ADAP Changes Create Gaps in HIV Treatment Access https://ml.globenewswire.com/media/YTc5NzBiN2ItNDFmYy00MjgxLWJkOGYtMWVmZjk2ODRiM2JkLTUwMDEzNDg1Ny0yMDI2LTA0LTA2LWVu/tiny/MISTR.png https://www.andorrahealthwatch.com/article/904124434-biodesix-announces-aacr-2026-posters-and-presentations-highlighting-novel-diagnostic-test-discovery-pipeline-development Andorra Health Watch en PressRelease 2026-04-06T15:43:00+00:00 Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development https://ml.globenewswire.com/media/b2fd8e3c-ff04-47d9-938d-93c9c961ccc3/small/bdsx-logo-1200x240-png.png https://www.andorrahealthwatch.com/article/904119613-yuzu-health-raises-35-million-series-a-to-modernize-health-insurance-plan-infrastructure Andorra Health Watch en PressRelease 2026-04-06T15:00:00+00:00 Yuzu Health Raises $35 Million Series A to Modernize Health Insurance Plan Infrastructure https://ml.globenewswire.com/media/ZTNkMDYxNWQtZmVjYS00M2RlLWI0OWYtMzA2MGY0YjhlN2E2LTEzMjIzODUtMjAyNi0wNC0wNi1lbg==/tiny/Yuzu-Health.png https://www.andorrahealthwatch.com/article/904119642-hairclub-launches-100-000-aderans-helping-hearts-fund-to-support-employees-facing-life-s-unexpected-hardships Andorra Health Watch en PressRelease 2026-04-06T15:00:00+00:00 HairClub Launches $100,000 Aderans Helping Hearts Fund to Support Employees Facing Life’s Unexpected Hardships https://ml.globenewswire.com/media/MDFmYjQwOTktMzE2MS00NTQ1LWI0ZDMtN2I4OWM2NDJjYzZjLTUwMDE1MzY4OS0yMDI2LTA0LTA2LWVu/tiny/HairClub.png https://www.andorrahealthwatch.com/article/904119717-celldex-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares Andorra Health Watch en PressRelease 2026-04-06T14:53:52+00:00 Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://ml.globenewswire.com/media/7a6cc287-087f-4e97-878f-7c1ed1dc5949/small/celldex-logo-rgb-png.png https://www.andorrahealthwatch.com/article/904115336-sienna-senior-living-recognized-by-the-globe-and-mail-s-women-lead-here-benchmark Andorra Health Watch en PressRelease 2026-04-06T14:25:00+00:00 Sienna Senior Living recognized by The Globe and Mail’s Women Lead Here Benchmark https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://www.andorrahealthwatch.com/article/904111237-al-anon-family-groups-celebrates-75-years-of-recovery-providing-help-and-hope-to-families Andorra Health Watch en PressRelease 2026-04-06T14:00:00+00:00 Al‑Anon Family Groups Celebrates 75 Years of Recovery — Providing Help and Hope to Families https://ml.globenewswire.com/media/293e2cf1-ce41-48e5-a66c-8a69496d5d01/small/al-anon-family-groups-logo.jpg https://www.andorrahealthwatch.com/article/904111343-adaptin-bio-shares-to-be-quoted-on-the-otcqb-under-ticker-symbol-aptn Andorra Health Watch en PressRelease 2026-04-06T14:00:00+00:00 Adaptin Bio Shares to be Quoted on the OTCQB Under Ticker Symbol APTN https://ml.globenewswire.com/media/89fb59f4-0171-4319-995d-70be0b36378b/small/logo-png.png https://www.andorrahealthwatch.com/article/904107243-9-66-bn-gastroenterology-products-market-forecasts-to-2034-rising-aging-population-advancing-endoscopic-tech-and-expanding-healthcare-in Andorra Health Watch en PressRelease 2026-04-06T13:29:11+00:00 $9.66+ BN Gastroenterology Products Market Forecasts to 2034: Rising aging population, advancing endoscopic tech, and expanding healthcare in developing regions https://ml.globenewswire.com/media/1f4cf0ab-7d76-4136-a6dc-a5545f80f538/small/zion-market-research-jpg.jpg https://www.andorrahealthwatch.com/article/904107250-zhengye-biotechnology-holding-limited-announces-implementation-of-dual-class-share-structure Andorra Health Watch en PressRelease 2026-04-06T13:25:00+00:00 Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure https://ml.globenewswire.com/media/9f44f819-7666-4ef0-b9e0-d50035c2a412/small/zybt-logo-png.png https://www.andorrahealthwatch.com/article/904107196-curanex-highlights-patient-case-study-supporting-potential-of-phyto-n-in-cancer-cachexia-and-advanced-cancer-supportive-care Andorra Health Watch en PressRelease 2026-04-06T13:17:00+00:00 Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care https://ml.globenewswire.com/media/29bc3de5-6a82-4a17-a165-6a79eef16d74/small/logo-png.png https://www.andorrahealthwatch.com/article/904103439-egg-medical-launches-eggnest-complete-flex-apron-free-protection-without-construction-downtime-or-disruption Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical Launches EggNest™ Complete Flex: Apron-Free Protection Without Construction, Downtime or Disruption https://ml.globenewswire.com/media/14f028e0-82c4-433b-a70a-84b9ad7c33c6/medium/eggnest-complete-flex.jpg https://www.andorrahealthwatch.com/article/904103443-oncolytics-biotech-announces-type-c-fda-meeting-to-discuss-single-arm-registrational-pathway-for-pelareorep-in-anal-cancer Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer https://ml.globenewswire.com/media/4dca5efc-ee4e-4e0a-b42d-7b45369d75da/small/oncy-jpg.jpg https://www.andorrahealthwatch.com/article/904103447-flare-therapeutics-announces-three-upcoming-poster-presentations-at-aacr-annual-meeting-2026 Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Flare Therapeutics Announces Three Upcoming Poster Presentations at AACR Annual Meeting 2026 https://ml.globenewswire.com/media/fbcb69a8-bb9a-4d13-b91e-c43f05ec2ee1/small/flaretx-logo-overlightbg-png.png https://www.andorrahealthwatch.com/article/904103449-egg-medical-bringt-eggnest-complete-flex-auf-den-markt-schutz-ohne-sch-rzen-ohne-bauarbeiten-ausfallzeiten-oder-betriebsunterbrechungen Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical bringt EggNest™ Complete Flex auf den Markt: Schutz ohne Schürzen, ohne Bauarbeiten, Ausfallzeiten oder Betriebsunterbrechungen https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103453-egg-medical-lanza-eggnest-complete-flex-protecci-n-sin-delantal-sin-obras-ni-interrupciones Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical lanza EggNest™ Complete Flex: protección sin delantal, sin obras ni interrupciones https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103457-egg-medical-pr-sente-eggnest-complete-flex-une-protection-sans-tablier-sans-travaux-sans-interruption-de-service-ni-perturbation Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical présente EggNest™ Complete Flex : une protection sans tablier, sans travaux, sans interruption de service ni perturbation https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103458-egg-medical-eggnest-complete-flex Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical משיקה את EggNest™ Complete Flex: הגנה ללא סינר, ללא בנייה, השבתה או שיבושים https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103462-egg-medical-meluncurkan-eggnest-complete-flex-perlindungan-bebas-apron-tanpa-pekerjaan-konstruksi-waktu-henti-atau-gangguan Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical Meluncurkan EggNest™ Complete Flex: Perlindungan Bebas Apron Tanpa Pekerjaan Konstruksi, Waktu Henti, atau Gangguan https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103469-eggnest-complete-flex Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 エッグ・メディカル、エッグネスト・コンプリート・フレックス (EggNest™ Complete Flex) を発売: 工事や稼働停止、業務中断なく、エプロン不要の防護を実現 https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103472-egg-medical-eggnest-complete-flex Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical, 별도 공사나 다운타임 없이 납 앞치마 불필요한 방사선 보호 솔루션 ‘EggNest™ Complete Flex’ 출시 https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103474-egg-medical-lancarkan-eggnest-complete-flex-perlindungan-tanpa-apron-tanpa-keperluan-kerja-pembinaan-masa-henti-atau-gangguan Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical Lancarkan EggNest™ Complete Flex: Perlindungan Tanpa Apron Tanpa Keperluan Kerja Pembinaan, Masa Henti atau Gangguan https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103475-egg-medical-lan-a-eggnest-complete-flex-prote-o-sem-avental-sem-constru-o-tempo-de-inatividade-ou-interrup-o Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical Lança EggNest™ Complete Flex: Proteção Sem Avental, Sem Construção, Tempo de Inatividade ou Interrupção https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103507-egg-medical-eggnest-complete-flex Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical เปิดตัว EggNest™ Complete Flex รุ่นป้องกันแบบไม่ต้องใช้เสื้อป้องกัน โดยไม่ต้องมีการก่อสร้าง ไม่ต้องหยุดการดำเนินงาน และไม่ขัดจังหวะการทำงา… https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103509-egg-medical-eggnest-complete-flex Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical 推出 EggNest™ Complete Flex：无需施工、停机或中断即可实现无铅衣防护 https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103516-egg-medical-eggnest-complete-flex Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Egg Medical 推出 EggNest™ Complete Flex：免穿鉛圍的防護解決方案，免工程、不停機、無中斷 https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png https://www.andorrahealthwatch.com/article/904103575-stress-awareness-month-signals-shift-away-from-always-on-living Andorra Health Watch en PressRelease 2026-04-06T13:00:00+00:00 Stress Awareness Month Signals Shift Away from “Always-On” Living https://ml.globenewswire.com/media/b847767e-6b43-48ae-ba24-0c320ae99e0f/medium/national-stress-awareness-month.jpeg https://www.andorrahealthwatch.com/article/904103552-onemednet-announces-strong-2025-financials-and-advances-ai-driven-irwd-powered-by-palantir-foundry-enabling-conversational-search-on-real-time Andorra Health Watch en PressRelease 2026-04-06T12:50:00+00:00 OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data https://ml.globenewswire.com/media/a356ae1d-a3c0-49e3-81b5-f19be76513d0/small/onemednet-jpg.jpg https://www.andorrahealthwatch.com/article/904103518-akari-therapeutics-announces-strategic-partnership-with-wuxi-xdc-to-advance-development-of-its-novel-adc-payload-targeting-rna-splicing Andorra Health Watch en PressRelease 2026-04-06T12:45:00+00:00 Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing https://ml.globenewswire.com/media/8d978f50-07a9-40a3-be69-45f51ccd94d9/small/akari-logo-1-jpg.jpg https://www.andorrahealthwatch.com/article/904100059-abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Andorra Health Watch en PressRelease 2026-04-06T12:30:00+00:00 Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/f11f9f14-9744-4666-aef3-9771488c41bd/small/thumb-1740-12-silhouette-vertical-full-color-png.png https://www.andorrahealthwatch.com/article/904100065-stablecoin-development-corporation-begins-trading-on-nyse-american-under-ticker-sdev Andorra Health Watch en PressRelease 2026-04-06T12:30:00+00:00 Stablecoin Development Corporation Begins Trading on NYSE American Under Ticker “SDEV” https://ml.globenewswire.com/media/NDdlZTYyYTAtY2U1Ni00MzY2LWI2MTQtMDI5MDk0MDNhYjVkLTEwMjg2MTQtMjAyNi0wNC0wNi1lbg==/tiny/Stablecoin-Development-Corpora.png https://www.andorrahealthwatch.com/article/904100133-tomi-environmental-solutions-inc-announces-surge-in-steramist-adoption-across-compounding-pharmacy-industry-amid-tightening-regulatory-standards Andorra Health Watch en PressRelease 2026-04-06T12:30:00+00:00 TOMI Environmental Solutions, Inc. Announces Surge in SteraMist Adoption Across Compounding Pharmacy Industry Amid Tightening Regulatory Standards https://ml.globenewswire.com/media/f8c7c513-0121-4507-84b7-3680626d9cf3/small/tomi-jpg.jpg https://www.andorrahealthwatch.com/article/904100107-stereotaxis-announces-fda-clearance-and-launch-of-synchrony-system Andorra Health Watch en PressRelease 2026-04-06T12:06:00+00:00 Stereotaxis Announces FDA Clearance and Launch of Synchrony System https://ml.globenewswire.com/media/95a5b8ca-b7c0-4c80-8ca7-063ef10706c3/small/stereotaxis-logo-new-tagline-black-text-png.png https://www.andorrahealthwatch.com/article/904100079-scienture-provides-annual-shareholder-update-outlining-significant-progress-and-strategic-priorities-for-the-year-ahead Andorra Health Watch en PressRelease 2026-04-06T12:05:00+00:00 Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead https://ml.globenewswire.com/media/56382978-c242-4bdd-b491-e6966e27d4ed/small/logo-png.png https://www.andorrahealthwatch.com/article/904096500-geron-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/e184bb51-5636-436e-8964-15613f24ca1f/small/geron-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904096520-inspire-medical-systems-inc-to-report-first-quarter-2026-financial-results-on-may-4-2026 Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 Inspire Medical Systems, Inc. to Report First Quarter 2026 Financial Results on May 4, 2026 https://ml.globenewswire.com/media/194e83a5-3f7e-4805-88ce-da2e0ab594df/small/inspire-primary-logo-rgb-daylight-002-png.png https://www.andorrahealthwatch.com/article/904096550-avalyn-appoints-jon-congleton-seasoned-biopharmaceutical-executive-to-its-board-of-directors Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors https://ml.globenewswire.com/media/84d7bff4-ce17-433b-8c71-aa20c30f9f43/small/avalyn-logo-final-png.png https://www.andorrahealthwatch.com/article/904096557-verrica-pharmaceuticals-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/4938c2eb-43f1-4f6c-a1e1-82ab7fb66c3b/small/verrica-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904096615-aveanna-healthcare-announces-second-annual-aveanna-cares-month-of-service Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 Aveanna Healthcare Announces Second Annual Aveanna Cares Month of Service https://ml.globenewswire.com/media/d3896f9e-a6a1-48c1-a8f7-d9ba5d7433d6/small/aveanna-healthcare-500x262-png.png https://www.andorrahealthwatch.com/article/904096643-tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor https://ml.globenewswire.com/media/311d9377-979c-4384-9258-5b496e854edb/small/tenvie-logo-gradient-rgb-png.png https://www.andorrahealthwatch.com/article/904096651-phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/0baa6f51-c6cb-4b21-a4e0-573a18b8171c/small/phathom-pharm-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904096655-praxis-precision-medicines-announces-positive-results-from-the-embrave-part-a-trial-of-elsunersen-in-patients-with-scn2a-early-onset-developmental-and Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.andorrahealthwatch.com/article/904096727-anna-autism-care-appoints-ariana-boutain-phd-bcba-d-as-chief-clinical-officer Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 ANNA Autism Care Appoints Ariana Boutain, PhD, BCBA-D as Chief Clinical Officer https://ml.globenewswire.com/media/NWMwMTNkZjMtYTQwYi00YjY3LTkzNjctOWU3ZGMyZTY3Y2ZiLTEzMjA4ODAtMjAyNi0wNC0wNi1lbg==/tiny/ANNA-HEALTH-INCORPORATED.png https://www.andorrahealthwatch.com/article/904096753-new-locket-data-accepted-in-leading-electrophysiology-journal Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 New LockeT Data Accepted in Leading Electrophysiology Journal https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://www.andorrahealthwatch.com/article/904096759-extendicare-announces-timing-of-2026-first-quarter-results-and-conference-call Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 Extendicare Announces Timing of 2026 First Quarter Results and Conference Call https://ml.globenewswire.com/media/6d631964-eede-4e2c-912c-58ab7d1dc35f/small/extendicare-jpg.jpg https://www.andorrahealthwatch.com/article/904096792-axe-compute-names-kyle-okamoto-president-adding-deep-infrastructure-systems-expertise-to-executive-team Andorra Health Watch en PressRelease 2026-04-06T12:00:00+00:00 Axe Compute Names Kyle Okamoto President, Adding Deep Infrastructure Systems Expertise to Executive Team https://ml.globenewswire.com/media/0722059f-4d31-435e-974f-ff669a2cb2e4/small/axe-compute.png https://www.andorrahealthwatch.com/article/904092950-organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2026-financial-results-on-may-7-2026 Andorra Health Watch en PressRelease 2026-04-06T11:30:00+00:00 Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026 https://ml.globenewswire.com/media/9c2f551f-b7b2-403a-bf43-78f1889401e5/small/organogenesis-jpg.jpg https://www.andorrahealthwatch.com/article/904092960-medicus-pharma-submits-optimized-phase-2-study-protocol-to-u-s-fda-for-teverelix-in-acute-urinary-retention Andorra Health Watch en PressRelease 2026-04-06T11:30:00+00:00 Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention https://ml.globenewswire.com/media/0f5af1d1-dfba-4810-baac-d1922c0558c1/small/medicus-logo-rgb-05-aspect-1500px-globe-newswire-2-jpg.jpg https://www.andorrahealthwatch.com/article/904092976-kraig-biocraft-laboratories-shatters-production-record-delivering-over-1-3-metric-tons-of-spider-silk-cocoons-in-a-single-month-a-5x-increase-over Andorra Health Watch en PressRelease 2026-04-06T11:05:00+00:00 Kraig Biocraft Laboratories Shatters Production Record, Delivering Over 1.3 Metric Tons of Spider Silk Cocoons in a Single Month, A 5X Increase Over Previous High https://ml.globenewswire.com/media/bd9626d2-4b5e-4f55-8b54-c8300fa5bef5/medium/bam1-recombinant-spider-silk-cocoons.jpg https://www.andorrahealthwatch.com/article/904089915-invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Andorra Health Watch en PressRelease 2026-04-06T11:01:00+00:00 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/7bf12f50-1073-4ce7-81ac-89426c07add3/small/untitled-design-2-png.png https://www.andorrahealthwatch.com/article/904089912-stipple-bio-emerges-from-stealth-with-oversubscribed-100-million-series-a-financing-to-advance-stp-100-into-early-clinical-studies-and-advance-a Andorra Health Watch en PressRelease 2026-04-06T11:00:00+00:00 Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform https://ml.globenewswire.com/media/96c458bd-cad2-4343-89d4-8c60bcfde0a5/small/stipple-no-name-logo-png.png https://www.andorrahealthwatch.com/article/904089917-biocryst-appoints-sandeep-m-menon-chief-research-and-development-officer Andorra Health Watch en PressRelease 2026-04-06T11:00:00+00:00 BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg https://www.andorrahealthwatch.com/article/904089923-sagimet-biosciences-announces-poster-and-oral-presentations-at-the-fueling-mash-metabolic-drivers-and-inflammatory-crosstalk-keystone-symposium-and Andorra Health Watch en PressRelease 2026-04-06T11:00:00+00:00 Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/e944daed-3f71-402b-bb23-82149e5c0d26/small/sagimet-logo-for-light-bg-fin-png.png https://www.andorrahealthwatch.com/article/904089924-immunocore-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-06T11:00:00+00:00 Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference https://ml-eu.globenewswire.com/media/bcaafaab-2536-4b4b-899c-9913925b6e4b/small/immunocore-logo-2018.png https://www.andorrahealthwatch.com/article/904089932-agios-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-april-29-at-8-00-a-m-et Andorra Health Watch en PressRelease 2026-04-06T11:00:00+00:00 Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET https://ml.globenewswire.com/media/c7d64dad-71c8-47cc-a58d-c93a49ce8f01/small/agios-2021-logo-png.png https://www.andorrahealthwatch.com/article/904089955-opus-genetics-solidifies-leadership-position-in-gene-therapy-development-for-inherited-retinal-diseases-with-strategic-long-term-financing-by-oberland Andorra Health Watch en PressRelease 2026-04-06T11:00:00+00:00 Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital https://ml.globenewswire.com/media/468baef1-3b2d-4353-a17e-cb41b45ee6ef/small/opus-rgb-r-jpg.jpg https://www.andorrahealthwatch.com/article/904089957-nrx-pharmaceuticals-nasdaq-nrxp-announces-fda-labeling-alignment-for-nrx-s-preservative-free-ketamine-application Andorra Health Watch en PressRelease 2026-04-06T11:00:00+00:00 NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://www.andorrahealthwatch.com/article/904089969-sharps-technology-reports-2025-year-end-results-and-highlights-continued-execution-of-solana-treasury-strategy Andorra Health Watch en PressRelease 2026-04-06T11:00:00+00:00 Sharps Technology Reports 2025 Year-End Results and Highlights Continued Execution of Solana Treasury Strategy https://ml.globenewswire.com/media/7e8b9bfa-42f5-446c-932a-41a01c25ed6b/small/sharps-technology-nasdaq-stss-white-background-png.png https://www.andorrahealthwatch.com/article/904089975-neumora-therapeutics-to-participate-in-25th-annual-needham-virtual-healthcare-conference Andorra Health Watch en PressRelease 2026-04-06T11:00:00+00:00 Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/48256578-6cd3-4332-bf9b-2f52cfa248b7/small/neumora-logo-jpg.jpg https://www.andorrahealthwatch.com/article/904086918-beacon-biosignals-upsizes-series-b-financing-to-over-97-million Andorra Health Watch en PressRelease 2026-04-06T10:30:00+00:00 Beacon Biosignals Upsizes Series B Financing to Over $97 Million https://ml.globenewswire.com/media/0485bb01-d362-473e-8fae-a6cab3b804aa/small/beacon-logo-inline-1-jpg.jpg https://www.andorrahealthwatch.com/article/904084259-profusa-expands-into-multi-billion-dollar-precision-diagnostics-market-with-30m-letter-of-intent-for-a-panomics-platform Andorra Health Watch en PressRelease 2026-04-06T10:00:00+00:00 Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform https://ml.globenewswire.com/media/a8137a61-b858-48da-9e47-1f1bf8f6ddba/small/profusa-logo-jpg.jpg